Address
1601 Trapelo Road
Waltham, MA 02451
United States of America (the)
Phone
781 819 0080
Website
Sector
Healthcare
Industry
Biotechnology
Employees
99
First IPO Date
August 06, 2021
| Name | Title | Pay | Year Born |
| Julie Green | Chief Human Resources Officer | 542,353 | 1976 |
| Timothy Lee | Chief Commercial Officer | 706,866 | 1974 |
| William E. Duke Jr. | Chief Financial Officer, Principal Accounting Officer & Principal Executive Officer | 752,777 | 1972 |
| Jill Andersen | Chief Legal Officer & Corporate Secretary | 775,710 | 1973 |
| Robert D. Allen | Chief Scientific Officer | 828,180 | 1970 |
| Rachael Gerlach | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Michael J. Mina | Chief Medical Officer | 0 | 1985 |
| Katie Falzone | Senior Vice President of Finance | 0 | N/A |
| Kristie Coneys Kuhl | Chief Communications Officer | 0 | N/A |
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.